IMU 0.00% 10.5¢ imugene limited

sorry...copy and pasted the wrong part of the rticle, although...

  1. 757 Posts.
    lightbulb Created with Sketch. 631
    sorry...copy and pasted the wrong part of the rticle, although its all relevant.

    Gilead & Forty Seven

    Further cementing Gilead’s ambitions in cancer, this $4.9 billion deal adds an antibody targeting several blood cancers to the company’s research pipeline.

    Forty Seven is based in Menlo Park, a short drive away from Gilead’s base in Foster City, and is developing magrolimab, which is targeting myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), and diffuse large B-cell lymphoma (DLBCL).

    A potential first-in-class therapy, magrolimab targets CD47, which produces a “do not eat me” signal that allows cancer cells to avoid destruction (an area AbbVie has almost invested significantly in).

    By targeting CD47 it’s hoped that magrolimab will allow the patient’s own innate system to engulf and eradicate cancer cells.

    The company presented promising results from a phase 1b study of magrolimab in patients with MDS and AML at the American Society of Hematology meeting in December.

 
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Last
10.5¢
Change
0.000(0.00%)
Mkt cap ! $768.4M
Open High Low Value Volume
10.5¢ 10.8¢ 10.0¢ $746.7K 7.120M

Buyers (Bids)

No. Vol. Price($)
176 10004604 10.0¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 420568 8
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
10.3¢
  Change
0.000 ( 2.40 %)
Open High Low Volume
10.3¢ 10.5¢ 10.3¢ 1930285
Last updated 15.59pm 28/03/2024 ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.